NCT06694805
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
Active, Not Recruiting
PHASE3Ages 12+InterventionalTreatmentViiV Healthcare
~326 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:CAB LA + RPV LAOral ART
At a glance
Recruiting sites
0 of 85 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with virologic suppression after the CAB LA + RPV LA treatment compared to oral ART
Measured over At Month 6
Conditions
Where it's being run
85 sites across 29 statesSpain24
Argentina7
New York5
Italy5
Florida4
Germany4
California3
Georgia3
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age
Type of Participant and Disease Characteristics 2.HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA VL.
Pregnancy, Sex and Contraceptive/Barrier Requirements 5. Person of childbearing potential (POCBP) must have a negative serum or urine pregnancy test at screening and on Day 1.
Informed Consent/Assent 6.Informed consent/Assent must be provided as follows:
What this trial measures
- Number of participants with virologic suppression after the CAB LA + RPV LA treatment compared to oral ARTAt Month 6
A virologic suppression is defined by HIV-1 RNA less than (\<) 50 copies (c)/mL.